Phase 2 RCT in 166 men with metastatic castration-resistant prostate cancer: adding metformin to enzalutamide did not improve 15-month disease-control rate (52% vs 56%, p=0.64) or secondary end points. Post hoc, a possible benefit in PTEN-expressing tumours.
Secondary analysisn = 166
Gillessen et al. Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)